Droperidol: Difference between revisions
Elcatracho (talk | contribs) |
Elcatracho (talk | contribs) |
||
| Line 31: | Line 31: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*[[Prolonged QT]], torsades, ventricular tachycardia, cardiac arrest | *[[Prolonged QT]], [[torsades]], [[ventricular tachycardia]], [[cardiac arrest]] | ||
**''Note: effect on QT interval is dose-dependent'' | **''Note: effect on QT interval is dose-dependent'' | ||
**In 2001, FDA gave black box warning for risk of [[torsades de pointes]], however this | **In 2001, FDA gave black box warning for risk of [[torsades de pointes]], however there was little evidence to support this | ||
**Large cohort of patients in ED showed safety of its administration<ref>Gaw CM, Cabrera D, Bellolio F, Mattson AE, Lohse CM, Jeffery MM. Effectiveness and safety of droperidol in a United States emergency department. Am J Emerg Med. 2020;38(7):1310-1314. doi:10.1016/j.ajem.2019.09.007</ref> | **Large cohort of patients in ED showed safety of its administration<ref>Gaw CM, Cabrera D, Bellolio F, Mattson AE, Lohse CM, Jeffery MM. Effectiveness and safety of droperidol in a United States emergency department. Am J Emerg Med. 2020;38(7):1310-1314. doi:10.1016/j.ajem.2019.09.007</ref> | ||
*Neuroleptic malignant syndrome | *[[Neuroleptic malignant syndrome]] | ||
*Anaphylaxis | *[[Anaphylaxis]] | ||
===Common=== | ===Common=== | ||
Revision as of 23:06, 13 March 2021
Administration
- Type: antipsychotic, antiemetics
- Dosage Forms: 5mg/2mL
- Routes of Administration: IV/IM
- Common Trade Names: Inapsine
Adult Dosing
Combative patient
- 5-10mg IV
- 10mg IM
Headache
- 2.5mg IV or 2.5-5mg IM
Nausea/vomiting
- 0.625-2.5mg IV
Pediatric Dosing
Nausea/vomiting
- 2-12yo: 0.015-0.1mg/kg IV/IM
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: Administer with caution
- Hepatic dosing: Administer with caution
Contraindications
- Allergy to class/drug
- Known or suspected prolonged QT
Adverse Reactions
Serious
- Prolonged QT, torsades, ventricular tachycardia, cardiac arrest
- Note: effect on QT interval is dose-dependent
- In 2001, FDA gave black box warning for risk of torsades de pointes, however there was little evidence to support this
- Large cohort of patients in ED showed safety of its administration[1]
- Neuroleptic malignant syndrome
- Anaphylaxis
Common
- Somnolence, dysphoria
- Anxiety, restlessness, hyperactivity
- Hypotension
- Tachycardia
Pharmacology
- Half-life: 123-147m (adults), 75-127m (children)
- Metabolism: hepatic
- Excretion: mostly renal
Mechanism of Action
- Dopamine (D2) antagonist. Some serotonergic, histaminergic, and α-adrenergic effect
Comments
See Also
References
- ↑ Gaw CM, Cabrera D, Bellolio F, Mattson AE, Lohse CM, Jeffery MM. Effectiveness and safety of droperidol in a United States emergency department. Am J Emerg Med. 2020;38(7):1310-1314. doi:10.1016/j.ajem.2019.09.007